個股熱度排行 | 11月1日港股盤前
根據uSMART輿情監測數據,從31日晚間到1日港股盤前時間段,市場關注指數最高的2只股票是龍湖集團、瑞科生物-B。
11月1日—港股關注排行TOP2

龍湖集團

關注度第一爲龍湖集團,該股上個交易日收盤下跌23.78%,報於10.00港元。近5個交易日累計下跌38.35%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
創始人辭職+行業不振 龍湖集團股票暴跌4.7%,2022年總跌幅已達51%!
龍湖集團獲控股股東購買500萬美元優先票據
瑞科生物-B

關注度第二爲瑞科生物-B,該股上個交易日收盤上漲0.20%,報於24.50港元。近5個交易日累計上漲0.82%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
瑞科生物建議定向發行內資股 上限5,795萬股
瑞科生物-B擬向不超35名境內機構投資者發行不超5795.6萬股內資股
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.